Enveric Biosciences Inc (ENVB) - Total Liabilities
Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has total liabilities worth $905.88K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Enveric Biosciences Inc annual equity growth to track the company's year-over-year net asset growth rate.
Enveric Biosciences Inc - Total Liabilities Trend (1994–2024)
This chart illustrates how Enveric Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Enveric Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
Enveric Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Enveric Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
USA | $49.14 Million |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
Germany | €7.71 Million |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
USA | $12.77 Million |
|
Eco Animal Health Group Plc
LSE:EAH
|
UK | GBX21.57 Million |
|
Jade Leader Corp
V:JADE
|
Canada | CA$456.03K |
|
Maven Income And Growth Vct 3 Plc
LSE:MIG3
|
UK | GBX556.00K |
|
DP Poland Plc
LSE:DPP
|
UK | GBX19.33 Million |
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
India | Rs142.01 Million |
Liability Composition Analysis (1994–2024)
This chart breaks down Enveric Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enveric Biosciences Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enveric Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enveric Biosciences Inc (1994–2024)
The table below shows the annual total liabilities of Enveric Biosciences Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.49 Million | -36.43% |
| 2023-12-31 | $2.34 Million | -41.35% |
| 2022-12-31 | $4.00 Million | -9.45% |
| 2021-12-31 | $4.41 Million | +547.81% |
| 2020-12-31 | $681.25K | -95.26% |
| 2019-12-31 | $14.38 Million | -23.81% |
| 2018-12-31 | $18.88 Million | -42.35% |
| 2017-12-31 | $32.75 Million | +17.61% |
| 2016-12-31 | $27.84 Million | +105.09% |
| 2015-12-31 | $13.58 Million | +151490.01% |
| 2014-12-31 | $8.96K | -63.73% |
| 2013-12-31 | $24.70K | -3.78% |
| 2012-12-31 | $25.67K | +43.43% |
| 2011-12-31 | $17.89K | -64.66% |
| 2010-12-31 | $50.64K | +326.75% |
| 2009-12-31 | $11.87K | -44.04% |
| 2008-12-31 | $21.21K | -55.73% |
| 2007-12-31 | $47.90K | -44.99% |
| 2006-12-31 | $87.08K | -51.50% |
| 2005-12-31 | $179.52K | -73.06% |
| 2004-12-31 | $666.31K | +166.77% |
| 2003-12-31 | $249.77K | -21.21% |
| 2002-12-31 | $317.01K | -7.18% |
| 2001-12-31 | $341.54K | -57.64% |
| 2000-12-31 | $806.35K | -40.26% |
| 1999-12-31 | $1.35 Million | -44.83% |
| 1998-12-31 | $2.45 Million | +49.20% |
| 1997-12-31 | $1.64 Million | +87.79% |
| 1996-12-31 | $873.32K | +24.76% |
| 1995-12-31 | $700.00K | -22.22% |
| 1994-12-31 | $900.00K | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more